21.23
1.17 (5.83%)
| Penutupan Terdahulu | 20.06 |
| Buka | 20.20 |
| Jumlah Dagangan | 522,970 |
| Purata Dagangan (3B) | 677,127 |
| Modal Pasaran | 1,087,323,008 |
| Harga / Pendapatan (P/E Ke hadapan) | 94.34 |
| Harga / Jualan (P/S) | 2.65 |
| Harga / Buku (P/B) | 3.41 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Apr 2026 |
| Margin Keuntungan | 17.92% |
| Margin Operasi (TTM) | -9.46% |
| EPS Cair (TTM) | 1.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 17.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.98% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | 26.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 29.89 M |
| Pulangan Atas Aset (ROA TTM) | -5.20% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | CareDx, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.60 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.22% |
| % Dimiliki oleh Institusi | 99.39% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 26.00 (BTIG, 22.47%) | Beli |
| Median | 23.50 (10.69%) | |
| Rendah | 21.00 (Wells Fargo, -1.08%) | Pegang |
| Purata | 23.50 (10.69%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 18.64 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 26 Feb 2026 | 26.00 (22.47%) | Beli | 18.82 |
| Wells Fargo | 25 Feb 2026 | 21.00 (-1.08%) | Pegang | 18.46 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KENNEDY KEITH | 21.29 | - | 24,134 | 513,813 |
| Jumlah Keseluruhan Kuantiti Bersih | 24,134 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 513,813 | |||
| Purata Pembelian Keseluruhan ($) | 21.29 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KENNEDY KEITH | Pegawai | 20 Apr 2026 | Diperolehi (+) | 24,134 | 21.29 | 513,813 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |